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Available online 3 June 2016Cellular-Flice-like inhibitory protein (c-FLIP) is an apoptosis modulator known to inhibit the extrinsic apoptotic
pathway thus blocking Caspase-8 processing in the Death Inducing Signalling Complex (DISC). We previously
demonstrated that c-FLIP localizes at the endoplasmic reticulum (ER) and that c-FLIP-deﬁcientmouse embryonic
ﬁbroblasts (MEFs) display an enlarged ER morphology. In the present study, we have addressed the conse-
quences of c-FLIP ablation in the ER stress response by investigating the effects of pharmacologically-induced
ER stress in Wild Type (WT) and c-FLIP−/−MEFs. Surprisingly, c-FLIP−/−MEFs were found to be strikingly
more resistant than WT MEFs to ER stress-mediated apoptosis. Analysis of Unfolded Protein Response (UPR)
pathways revealed that Pancreatic ER Kinase (PERK) and Inositol-Requiring Enzyme 1 (IRE1) branch signalling
is compromised in c-FLIP−/− cells when compared with WT cells. We found that c-FLIP modulates the PERK
pathway by interfering with the activity of the serine threonine kinase AKT. Indeed, c-FLIP−/−MEFs display
higher levels of active AKT than WT MEFs upon ER stress, while treatment with a speciﬁc AKT inhibitor of c-
FLIP−/−MEFs subjected to ER stress restores the PERK but not the IRE1 pathway. Importantly, the AKT inhibitor
or dominant negative AKT transfection sensitizes c-FLIP−/− cells to ER stress-induced cell death while the ex-
pression of a constitutively active AKT reduces WT cells sensitivity to ER stress-induced death. Thus, our results
demonstrate that c-FLIP modulation of AKT activity is crucial in controlling PERK signalling and sensitivity to ER
stress, and highlight c-FLIP as a novel molecular player in PERK and IRE1-mediated ER stress response.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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c-FLIP1. Introduction
Disruption of endoplasmic reticulum (ER) homeostasis interferes
with protein folding and leads to the accumulation of unfolded and
misfolded proteins in the ER lumen. This condition, deﬁned as “ER
stress”, triggers a series of pathways collectively known as the Unfolded
Protein Response (UPR), which is an important adaptive response to ER
stress. TheUPR is designed to re-establish homeostasis by increasing the
ER folding capacity and reducing the ER client load. Indeed, UPR activa-
tion results in increased ER size, expression of genes involved in protein
folding and in the ER-associated protein degradation, and in a tempo-
rary reduction in global protein synthesis. However, if homeostasis can-
not be restored, theUPR leads cells to apoptosis [1]. The UPR is triggered
by three ER-transmembrane proteins that detect perturbations in the
ER and start a signalling cascade in the cytosol: Activating Transcription
Factor 6 (ATF6), Pancreatic ER Kinase (PERK), Inositol-Requiringistology, Forensic Medicine and
y, Sapienza University of Rome,
. This is an open access article underEnzyme 1 (IRE1). Although the mechanisms of activation underlying
these three sensors have yet to be fully elucidated, they clearly involve
the ER molecular chaperone Glucose Regulated Protein 78 (also
known as BIP). Under normal conditions, BIP binds to the ER luminal do-
main of the UPR sensor proteins and inactivates their signalling; in re-
sponse to accumulation of unfolded proteins in the ER lumen, BIP
dissociates from these sensors, thereby allowing the activation of their
proper signalling [2]. After onset of ER stress, ATF6 migrates from the
ER to the Golgi apparatus, undergoing a proteolytic cleavage that re-
leases a cytosolic domain that moves to the nucleus and acts as a tran-
scription factor promoting the transcription of UPR target genes
mainly involved in protein folding [3]. After BIP dissociation, PERK olig-
omerization and activation determine phosphorylation of the eukaryot-
ic translation initiation factor-2 (eIF2α) which, in turn, inhibits mRNA
translation and reduces the load on the ER. Furthermore, phosphorylat-
ed eIF2α triggers the translation of the mRNA of the Activating Tran-
scription Factor 4 (ATF4). The ATF4 targets include Growth Arrest and
DNA-Damage inducible protein-34 (GADD34), the UPR-inducible regu-
latory subunit of the Protein Phosphatase 1 (PP1C) that de-phosphory-
lates eIF2α and removes the translational arrest [4]. Another ATF4
target is CHOP, a transcription factor that moves to the nucleus and
up-regulates pro-apoptotic genes, thereby leading to programmed cellthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pathway to protect cells frommild or short-lasting ER stress by reducing
the load on the ER through translation attenuation, whereas when ER
stress is marked or prolonged it does not offer any protection and
leads to apoptosis via expression of the pro-apoptotic CHOP. The cyto-
solic domain of activated IRE1 possesses ribonucleolytic activity that
processes the mRNA of the transcription factor XBP1 through an atypi-
cal splicing mechanism that removes 22 nucleotides to produce the
spliced, active formXBP1s. XBP1s thenmigrates to the nucleus and con-
trols the transcription of genes encoding proteins involved in protein
folding, ER-associated protein degradation (ERAD) and enzymes of the
lipid biosynthesis pathways. XBP1s plays a critical role in the ER in-
crease in size upon ER stress [7]. However, sustained IRE-1 activation
can trigger apoptosis through its ability to activate BCL-2 family mem-
bers and caspases [8].
Other mechanisms besides BIP-mediated-activation of PERK and
IRE1 are known be involved in UPR regulation [9–16]. In particular Z.
Mounir et al. [15] recently reported a link between AKT and the PERK
pathway. They demonstrated that AKT inhibits PERK activation through
phosphorylation at T799, which blocks PERK and impairs its autophos-
phorylation at T980. The AKT interactors include the Cellular-Flice-like
inhibitory protein (c-FLIP), which is an anti-apoptotic protein that pre-
vents procaspase-8 processing at DISC and inhibits Death Receptor
(DR)-mediated apoptosis [17]. All three splicing variants, named c-
FLIPL, c-FLIPR and c-FLIPs, contain two tandem Death Effector Domains
(DEDs) at their N-terminal, which is structurally similar to the N-termi-
nal part of procaspase-8. The two DED motifs of c-FLIPR and c-FLIPs are
followed by a short and varying stretch of amino acids at the C-terminal.
By contrast, c-FLIPL contains a longer C-terminal caspase-like domain,
which is not active [18,19]. The structural differences between the c-
FLIP isoforms correlate with a different cellular localization and func-
tion; indeed, c-FLIPS,R are found in the cytosol alone, whereas c-FLIPL lo-
calizes in the nucleus, cytoplasm, ER and Mitochondria-Associated
Membranes (MAMs) [20–22]. Moreover, whereas the anti-apoptotic
role of c-FLIPS,R has been widely demonstrated, c-FLIPL has been report-
ed to exert the opposite effect on apoptosis regulation; c-FLIPL has been
shown to block Fas-induced Caspase-8 activation when expressed at
high levels, but to act as a pro-apoptotic molecule when its expression
level is moderate [23–25]. In addition to its involvement in apoptosis
modulation, c-FLIP plays important roles in controlling proliferation
[26] and cardiac hypertrophy after pressure overload [27]. Furthermore,
c-FLIP can activate several pro-survival signalling pathways by regulat-
ing proteins such as NF-κB, ERK and AKT [28–30]. More recently, we
demonstrated that c-FLIP−/− mouse embryonic ﬁbroblasts (MEFs)
display an enlarged ER structure and strong lipid accumulation [22,
31]. In the present study, we investigated ER stress response in c-
FLIP−/−MEFs. We were surprised to ﬁnd that c-FLIP ablation protects
cells from ER stress-mediated apoptosis because of a reduced induction
of UPR signalling. Our ﬁndings indicate that c-FLIP plays an important
role in PERK and IRE1-mediated ER stress response.
2. Materials and methods
2.1. Cell cultures and reagents
Wild type (WT) and c-FLIP−/−MEFswere obtained and cultured as
previously described [22].
Brefeldin A (Bref) (400 ng/ml), Thapsigargin (Tg) (1 μM) and
Tunicamycin (Tu) (1 μg/ml) were purchased from Sigma-Aldrich (St
Louis, MO, USA).
The following plasmids were used: 294 c-FLIPL, HA-E40K-AKT, HA-
AKT-K179M and the corresponding control vectors. Plasmid transfec-
tions were performed on subconﬂuent cells using lipofectamine 2000
reagent (Invitrogen, San Giuliano Milanese, Italy) according to
manufacturer's instructions. 24 h after transfection, cells were treated
with Tu (1 μg/ml) for 16 h.TheAKT inhibitor VIII (20 μM)was purchased fromCalbiochem (San
Diego, CA, USA). The vehicle DMSO was used as a control. Cells were
photographed on the selected hours of treatment by microscopy
(Axioskop 2 plus; Carl Zeiss Microimaging, Inc.). Images were obtained
at room temperature using an AxioCamHRC camera (Carl Zeiss
Microimaging, Inc., Milan, Italy) by Axiovision 3.1 software and assem-
bled in panels using Photoshop 7.0 (Adobe, Waltham, MA, USA).
2.2. Western blotting
Western blot analysis was carried out as previously described [31].
The sources of the primary antibodies were: anti-BIP/GRP78 from BD
Transduction Laboratories™ (USA); anti-β-actin from Sigma-Aldrich
(St. Louis, MO); anti-HA, anti-Cleaved Caspase-3, anti-PARP, anti-LC3,
anti-CHOP, anti-Phospho-eIF2α Ser51, anti-eIF2α, anti-Phospho-AKT
Ser 473 and anti-AKT from Cell Signaling Technology (Danvers, MA);
anti-Phospho-IRE1α Ser724 and anti-IRE1α from Novus Biologicals
(Littleton, CO); anti-CREB-2 and anti-XBP1s from Santa Cruz Biotech-
nology (Santa Cruz, CA). Secondary antibodies were horseradish perox-
idase-conjugated goat anti-mouse or anti-rabbit (Bio-Rad, Hercules,
CA).
2.3. Immunoﬂuorescence
Immunoﬂuorescence was performed as previously described [31].
To analyze the accumulation of LC3 II on autophagic vesicles 24 h after
plating, MEFs were treated with Bref (400 ng/ml) for 16 h before
being incubated overnight with the rabbit anti-LC3 (Cell Signaling Dan-
vers, MA); secondary goat anti-rabbit IgG-FITC (Sigma-Aldrich St. Louis,
MO) was then added to the samples for 1 h. Immunoﬂuorescence was
visualized using an AxioCamHRC camera by Axiovision 3.1 software
and images were assembled in panels using Photoshop 7.0.
2.4. Apoptosis assay
Apoptosis was evaluated by propidium iodide (PI) staining, as previ-
ously described [32].
2.5. Statistical analysis
Values are expressed asmean± standard error (s.e.m.). The statisti-
cal analyses were performed by Student's t-test; a value of P ≤ 0.05 and
P ≤ 0.01 was considered statistically signiﬁcant.
3. Results
3.1. c-FLIP−/−MEFs are resistant to ER stress-induced apoptosis
We recently demonstrated that c-FLIP−/− cells display an enlarged
ER morphology [22]. Since this morphological modiﬁcation may be as-
sociated with functional alterations [16], we decided to examine the ef-
fect of ER stress in WT and c-FLIP−/−MEFs. To this end, we cultured
WT and c-FLIP−/− cells in the presence of three distinct drugs that in-
duce ER stress: Thapsigargin (Tg), an inhibitor of the sarcoplasmic retic-
ulum and ER Ca2+-ATPase that reduces ER calcium levels by affecting
chaperone activity, Tunicamycin (Tu), which blocks glycosylation of
newly synthesized proteins thereby causing misfolding, and Brefeldin
A (Bref), which blocks forward transport between the ER and the
Golgi apparatus. After 16 h of treatment with each drug, we found
that c-FLIP−/− but not WT MEFs were resistant to ER stress-induced
cell death, as shown by bright-ﬁeld microscopic images (Fig. 1A). Inter-
estingly, propidium iodide staining and ﬂow cytometry revealed that a
signiﬁcant number of WT cells, though not of c-FLIP−/− cells, died
after induction of ER stress (Fig. 1B). Previous studies have demonstrat-
ed that prolonged ER stress activates apoptosis [33]. To determine
whether cell death, observed in WT cells, was consequent to an
Fig. 1. c-FLIP−/−MEFs are resistant to ER stress-induced apoptosis. (A) WT and c-FLIP−/−MEFs were treated with Brefeldin A (Bref) (400 ng/ml), Thapsigargin (Tg) (1 μM) and
Tunicamycin (Tu) (1 μg/ml) for 16 h and cell death was observed by bright-ﬁeld microscopic images. The images shown are representative of three independent experiments. (B) Cell
death was assessed by evaluating the percentage of cells with a subG1 DNA content by ﬂow-cytometry analysis of cells ﬁxed in ethanol and stained with Propidium Iodide. WT and c-
FLIP−/− cells were analyzed after incubation with Tg, Tu and Bref for 30 h. The data shown are the mean ± s.e.m. of three independent experiments. **P ≤ 0.01 WT versus c-FLIP
MEFs. Upon treatment with Bref for 3, 6 and 16 h (C) and with Tg, Tu and Bref for 16 h (D), WT and c-FLIP−/− cells were lysed, and protein simples were subjected to Western blot
analyses to detect cleavage of Caspase-3 and PARP. β-Actin was used as a loading control. Data shown are representative of three independent experiments. E: c-FLIP−/− cells were
transfected with a c-FLIPL vector, a control vector or mock-transfected. 24 h after transfection cells were treated with Tu for 16 h. Lysates were subjected to Western blot analyses to
detect c-FLIPL and Caspase-3 cleavage. β-Actin was used as a loading control. Data shown are representative of three independent experiments.
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cleavage of Caspase 3 and PARP upon treatment with Bref for 3, 6 and
16 h. In keepingwith the increased cell death ofWT cells, the activation
of Caspase-3 and PARP was already evident after 6 h, whereas in c-
FLIP−/− cells it was only observed after 16 h of treatment (Fig. 1C). Re-
duced sensitivity to ER-stress induced apoptosis in c-FLIP−/− MEFs
was also observed after treatment with Tg and Tu for 16 h (Fig. 1D).
As shown in Fig. 1E, when we transfected c-FLIP−/− MEFs with a c-
FLIPL plasmid we observed higher Caspase-3 cleavage after 16 h Tu
treatment as compared to Tu-treated control vector ormock transfected
cells (69.6 ± 5 vs 51.1 ± 3.8 or 40.9 ± 2.7 A.U.). This result demon-
strates that the speciﬁc isoform c-FLIPL is sufﬁcient to make c-
FLIP−/−MEFs more sensitive to ER stress-induced apoptosis. We and
others previously showed that TNFα and staurosporine cause apoptosis
in c-FLIP−/− cells at levels that are respectively higher than and com-
parable to those of WT MEFs [22,34]. These data demonstrate that both
extrinsic and intrinsic apoptotic pathways are intact in c-FLIP−/−
MEFs, thus suggesting that the higher resistance to ER stress observedin c-FLIP−/− cells may be due to differences in how UPR is activated
in c-FLIP−/− and WT cells.3.2. ER stress weakly activates autophagy in WT and c-FLIP−/− cells
It has been demonstrated that ER stress can also induce autophagy
[35]. To investigate whether the difference in sensitivity displayed by
our cells to ER stress was associated with different autophagy levels,
WT and c-FLIP−/− cells were treated with Bref, which was the stron-
gest inducer of cell death even in c-FLIP−/− cells (Fig. 1), and autoph-
agy was assayed at different times by immunodetection of the
membrane-bound form of LC3 (LC3 II). Bref caused a comparable in-
crease in LC3 II levels inWT and c-FLIP−/− cells (Fig. 2A). These results
are in agreementwith the formation of LC3 II punctate spots,which rep-
resent the accumulation of LC3 II on autophagic vesicles, observed in
both cell lines (Fig. 2B). These data suggest that ER stress weakly acti-
vates autophagy inWTand c-FLIP−/−MEFs to a similar extent, thereby
Fig. 2. ER stress activates autophagy to a slight and similar extent inWT and c-FLIP−/− cells. WT and c-FLIP−/−MEFs were treated with Bref for 3 to 16 h and cell lysates were used to
analyze LC3 I to LC3 II conversionbyWestern blotting (upper panel). The graph represents the densitometric values of LC3 II relative toβ-actin protein levels induced byBref (lower panel).
The data shown are the mean ± s.e.m. of three independent experiments. (B) Representative images of ﬂuorescence microscopy show LC3 II accumulation in WT and c-FLIP−/− cells
treated with Bref for 16 h and stained with anti-LC3 antibody (green). The images shown are representative of three independent experiments. Magniﬁcation: 400×.
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cess as a consequence of ER stress onset.
3.3. c-FLIP−/− cells display compromised PERK and IRE1 signalling upon
ER stress induction
To investigate possible differences in UPR activation that might
determine the differences in sensitivity to ER stress between WT and c-
FLIP−/− cells, we assessed the modulation of key players of the UPR.Fig. 3. c-FLIP−/− cells display compromised PERK and IRE1 UPR branch signalling under ER str
and cell lysateswere analyzedbyWestern blotting to examineBIP (A), P-eIF2α, eIF2α, ATF4 and
data shown are representative of three independent experiments.We ﬁrst analyzed the expression of one of the main ER chaperones, BIP,
which is up-regulated upon ER stress induction. Treatments with Bref,
Tg and Tu in both WT and c-FLIP−/− MEFs induced a rapid and
comparable increase in BIP expression at the reported time points,
thereby demonstrating that these drugs activate an ER stress response
in both cell lines (Fig. 3A).
Since we did not ﬁnd any signiﬁcant difference in ATF6 activation
between WT and c-FLIP−/− MEFs (data not shown), we focused on
the PERK and IRE1 branches of the UPR, which have been shown toess induction.WT and c-FLIP−/−MEFs were treatedwith Bref, Tg and Tu for 3, 6 and 16 h
CHOP (B) and P-IRE1, IRE1 andXBP1s levels (C).β-Actinwas used as a loading control. The
1266 S. Conti et al. / Cellular Signalling 28 (2016) 1262–1269play a critical role in activating apoptosis upon ER stress [1]. We ob-
served that upon Bref, Tg and Tu treatments P-eIF2α, ATF4 andCHOP in-
duction was compromised in c-FLIP−/− as compared with WT MEFs
(Fig. 3B), thus demonstrating that the PERK pathway was less active
in c-FLIP−/− cells.
Interestingly, althoughwe observed similar IRE1 phosphorylation in
both cell lines after ER stress induction, the expression of its target
XBP1s was drastically reduced in c-FLIP−/− MEFs alone (Fig. 3C).
These data reveal that c-FLIP ablation dramatically disrupts PERK and
IRE1 signalling in response to ER stress, hence suggesting that the resis-
tance to ER stress-induced apoptosis observed in c-FLIP−/−MEFs may
be a consequence of these UPR alterations.
3.4. c-FLIP−/− cells display greater AKT activation than WT
As c-FLIP has no catalytic activity, it is unlikely to directly regulate
the UPR components, though it may take part in a regulatory complex.
C. Quintavalle et al. [30] demonstrated that c-FLIP interacts with AKT
and inhibits its ability to bind to and regulate its substrate GSK3β, prob-
ably by sequesteringAKT and limiting its access to the target protein. In-
terestingly, we have previously demonstrated that a pool of c-FLIP
proteins localizes at ER [22]. There is also a considerable amount of ev-
idence showing that AKT, localized at ER, is phosphorylated in response
to ER stress [36], thereby allowing it to promote cell survival [11] and
control the PERK branch. Since PERK and IRE1 are ER resident proteins,
we hypothesized that the proximity of all these proteins may regulate
PERK and IRE1 signalling. To test whether c-FLIP, by binding to AKT,
modulates the UPR response, we ﬁrst analyzed P-AKT induction in WT
and c-FLIP−/− cells treated with the three ER stress inducers. As
shown in Fig. 4, c-FLIP−/−MEFs displayed higher levels of AKT phos-
phorylation at serine 473 thanWT cells, even in basal conditions. In ad-
dition, such AKT phosphorylation in c-FLIP−/− MEFs increased in a
time-dependent manner after ER stress induction, decreasing only
after 16 h of treatment. Remarkably, c-FLIP−/− cells started dying
after 16 h (Fig. 1D).Conversely, no remarkable differences in AKT phos-
phorylation at threonine 308 andmTOR phosphorylation at serine 2448
were found between WT and c-FLIP−/− MEFs upon Tu treatment
(Supplementary ﬁgure).
These data reveal that c-FLIP depletion increases AKT activation via
phosphorylation at serine 473, and that this increase is even more evi-
dent after ER stress onset.
3.5. Activation of AKT is involved in apoptosis resistance in c-FLIP−/− cells
upon ER stress induction
To investigate whether the P-AKT upregulation observed in c-
FLIP−/− cells correlates with a higher degree of resistance to ER
stress-induced apoptosis, we treated c-FLIP−/−MEFs with the AKT in-
hibitor VIII, a pharmacological inhibitor that targets the pleckstrin ho-
mology (PH) domain of AKT, thus completely blocking AKT activation.
We assessed the effect of combined AKT inhibitor VIII and Tu treatment
on cell viability and apoptotic response. As shown by bright-ﬁeldmicro-
scopic images (Fig. 5A), while single AKT inhibitor VIII or Tu treatment
had no effect on cell viability, the combined treatment signiﬁcantly sen-
sitized c-FLIP−/− cells to ER stress-induced death. Accordingly, weFig. 4. c-FLIP−/− cells display increased AKT activation compared with WT cells. Western blo
FLIP−/− cells treated with Bref, Tg and Tu for 3, 6 and 16 h. β-Actin was used as a loading confound higher Caspase-3 and PARP activation levels following combined
treatment than single Tu or AKT inhibitor VIII treatment (Fig. 5B). To
further conﬁrm the role of AKT in modulating the resistance to ER
stress-induced apoptosis, we transiently transfected WT MEFs with a
plasmid expressing constitutively active AKT (HA-E40K-AKT) and c-
FLIP−/− cells with dominant negative AKT (HA-AKT-K179M). Efﬁcient
plasmid transfection was revealed by both HA-AKT and P-AKTWestern
blot experiments, as shown in Fig. 5C and D. Transfected cells were
treated with Tu and successively cell death was investigated. As
shown in Fig. 5C, WT MEFs became less sensitive to Tu-induced cell
death, evaluated by Caspase-3 cleavage, when previously transfected
with HA-E40K-AKT plasmid as compared to control vector transfected
cells. Conversely, c-FLIP−/− MEFs became more sensitive to Tu-in-
duced cell death, evaluated by Caspase-3 cleavage, when previously
transfectedwithHA-AKT-K179Mplasmid as compared to control vector
transfected cells (Fig. 5D).
Altogether these results demonstrate that the increased phosphory-
lation and activation of AKT in c-FLIP ablated cells promotes cell survival
in response to ER stress.
3.6. Inhibition of AKT restores PERK but not IRE1 signalling pathway during
ER stress
We subsequently assessedwhether increased AKT activationwas in-
volved in the reduced activation of PERK and IRE1 pathways in c-
FLIP−/−MEFs. To this end,we analyzed the expression levels of targets
of these proteins upon the combined treatment with AKT inhibitor VIII
and Tu. AKT inhibition did not enhance IRE1 activation in c-FLIP−/−
cells upon Tu treatment, as demonstrated by comparable XBP1s induc-
tion in c-FLIP−/− cells treatedwith either Tu alone orwith Tu plus AKT
inhibitor VIII (Fig. 6A). In keeping with this ﬁnding, XBP1s expression
was also lower in c-FLIP−/− cells that underwent combined treatment
than in WT cells treated with Tu (Fig. 6B).
By contrast, when we investigated PERK signalling in c-FLIP−/−
cells, we observed signiﬁcantly higher ATF4 and CHOP expression
upon combined treatment with AKT inhibitor VIII and Tu than upon
Tu treatment alone (Fig. 6C). To ascertain whether AKT inhibition
completely restores the PERK pathway in FLIP−/− cells, we compared
the induction of ATF4 and CHOP expression in c-FLIP−/− upon com-
bined treatment with AKT inhibitor VIII and Tu with that of WT cells
treated with Tu alone. No differences were detected between the two
cell lines in ATF4 and CHOP expression after 6 h of treatment (Fig.
6D), thus demonstrating that AKT inhibition alone is sufﬁcient to restore
the activation of the PERK pathway upon ER stress induction to levels
comparable to those observed in WT cells. Thus AKT plays a critical
role in inhibiting the PERK pathway in c-FLIP−/− cells.
4. Discussion
In this work, we provide evidence of a novel role of c-FLIP protein in
the regulation of the UPR signalling pathway and ER stress mediated-
apoptosis. For the ﬁrst time, we demonstrate that c-FLIP−/− MEFs
are resistant to apoptosis induced by ER stress and that this resistance
correlates with compromised PERK and IRE1 UPR branch signalling. Int analyses for P-AKT at serine 473 and AKT of whole cell lysates obtained fromWT and c-
trol. Data shown are representative of three independent experiments.
Fig. 5. Activation of AKT is involved in apoptosis resistance in c-FLIP−/− cells upon ER stress induction. (A) c-FLIP−/−MEFswere treatedwith Tu for 16 hwith or without AKT inhibitor
VIII (20 μM), added 1 h before Tu, and cell death was observed by bright-ﬁeld microscopic images. The images shown are representative of three independent experiments. (B) Upon
treatment with Tu for 24 and 30 h with or without AKT inhibitor VIII, c-FLIP−/− cells were lysed and protein samples were subjected to Western blot analyses to evaluate P-AKT,
AKT, PARP and Cleaved Caspase-3 levels. The arrow indicates cleaved PARP. β-Actin was used as a loading control. The data shown are representative of three independent
experiments. (C) WT MEFs were transfected with constitutively active AKT (HA-E40K-AKT) or control vector and 24 h after transfection cells were treated with Tu for 16 h. Lysates
were subjected to Western blot analyses to evaluate P-AKT Ser 473, HA-AKT and Cleaved Caspase-3. β-Actin was used as a loading control. The data shown are representative of three
independent experiments. (D) c-FLIP−/−MEFs were transfected with dominant negative AKT (HA-AKT-K179M) or control vector and 24 h after transfection cells were treated with
Tu for 16 h. Lysates were subjected to Western blot analyses to evaluate P-AKT Ser 473, HA-AKT and Cleaved Caspase-3. β-Actin was used as a loading control. The data shown are
representative of three independent experiments.
1267S. Conti et al. / Cellular Signalling 28 (2016) 1262–1269addition, our results show that PERK branch inhibition in FLIP−/− cells
is due to higher AKT activation.
Besides its well-known role as an anti-apoptotic protein, c-FLIP has
been shown to be involved in other cellular functions. We recently de-
scribed its novel role as a modulator of ER morphology and ER-mito-
chondria crosstalk, showing that c-FLIPL localizes at ER and MAMs and
that c-FLIP−/− MEFs display an enlarged ER structure [22]. Several
proteins, localized as c-FLIP at ER andMAMs, are involved in the regula-
tion of ER stress response [10,16,37,38]. These proteins includeMitofusin 2 (Mfn 2), which has been studied extensively. An altered
ER morphology in Mfn2−/− cells modiﬁes the ER stress response. J.P.
Munoz et al. [16] demonstrated that Mfn2 ablation causes a dramatic
ER expansion,which increases upon ER stress. Thismorphological alter-
ation modiﬁes UPR activation and apoptosis sensitivity after ER stress
induction. Here we demonstrate that c-FLIP, which has previously
been shown to alter ER morphology [22], acts as a pro-apoptotic factor
in response to ER stress. Indeed, c-FLIP−/− MEFs are more resistant
than WT MEFs to apoptosis upon treatment with the three different
Fig. 6. Inhibition of AKT restores the PERK, but not IRE1, signalling pathway during ER stress. (A)Western blot analyses of P-AKT Ser 473, AKT, XBP1s and of ATF4 and CHOP (C) fromwhole
cell lysates of c-FLIP−/−MEFs treated with Tu for 3, 6 and 16 h with or without AKT inhibitor VIII. β-Actin was used as a loading control. Data shown are representative of three
independent experiments. XBP1s (B), ATF4 and CHOP (D) proteins were assessed by Western blotting to compare their expression levels in c-FLIP−/− cells treated with Tu plus AKT
inhibitor VIII and WT cells treated with Tu alone for 3, 6 and 16 h (upper panel). The histograms (lower panels) show the densitometric analysis of XBP1s, ATF4 and CHOP levels
relative to β-actin in both cell lines. Data shown are the mean ± s.e.m. of three independent experiments. *P ≤ 0.05 WT versus c-FLIP.
1268 S. Conti et al. / Cellular Signalling 28 (2016) 1262–1269drugs that induce ER stress. As it is known that the autophagic process
may have a cytoprotective effect upon ER stress induction [35], we ana-
lyzed the involvement of autophagy in the resistance that characterizes
c-FLIP−/− cells. We observed a comparable time-dependent increase
in LC3 II expression and punctate spot formation in both WT and c-
FLIP−/−MEFs, thus demonstrating that autophagy levels are similar
in both cell lines. This suggests that the reduced ER stress-induced apo-
ptosis in c-FLIP−/− cells is not due to an altered autophagic response.
In order to shed light on the molecular mechanism underlying the dif-
ferences in the sensitivity displayed by WT and c-FLIP−/− MEFs to
ER stress, we analyzed the activation of the three UPR branches. Upon
treatment with Bref, Tg and Tu, we found no differences in ATF6 activa-
tion between WT and c-FLIP−/− MEFs. By contrast, we observedimpaired PERK and IRE1 signalling in c-FLIP−/− cells.Wehypothesized
that the c-FLIP protein ER resident pool is able to regulate these ER res-
ident kinases thanks to their shared cellular localization. Remarkably,
the pathway initiated by ATF6, which is the only ER stress sensor that
moves from ER to the Golgi apparatus in response to ER stress, is not al-
tered in c-FLIP−/− cells. The pathways triggered by the ERmembrane-
located PERK and IRE1 are hindered. Since c-FLIP does not display any
catalytic activity, we hypothesized that it may interact with a regulator
of these sensors. In particular, we focused on AKT, a serine-threonine ki-
nase that prevents apoptosis induced by various stress conditions by
interacting with apoptotic modulators such as BAD [39], Caspase-9
[40], FOXO3 [41] and Bcl-w [42]. AKT has previously been shown to in-
teract with c-FLIPL, which inhibits its function and blocks its ability to
1269S. Conti et al. / Cellular Signalling 28 (2016) 1262–1269activate the substrate GSK3β [30]. Interestingly, several studies point to
the involvement of AKT in ER stress response. It has been observed that
the activation of ER-located AKT protects primary cultured glial cells
[36] and breast, lung and prostate cancer cell lines [11] from ER stress-
induced apoptosis. Z. Mounir et al. clariﬁed the molecular mechanism
underlying this process, demonstrating that activated AKT impairs
PERK autophosphorylation [15]. We found that upon ER stress induc-
tion, c-FLIP−/−MEFs displayed higher levels of AKT phosphorylation
at serine 473 than WT cells. When we interfered with AKT activity,
using the AKT inhibitor VIII, the PERK pathway activation was restored
and the resistance to ER stress-induced apoptosis in c-FLIP−/− cells
was partially reduced. This demonstrates that the absence of c-FLIP re-
sults in AKT activation, which in turn inhibits PERK signalling and pro-
motes cell survival in response to ER stress. C. Quintavalle and
colleagues showed that c-FLIP over-expression in HeLa cells did not
alter AKT phosphorylation levels in response to insulin but did inhibit
the ability of AKT to bind to and phosphorylate GSK3β. In addition to
this mechanism of AKT regulation, in the present manuscript we dem-
onstrate that c-FLIP also impairs AKT function by inhibiting its phos-
phorylation in a different cellular model, i.e. that of MEF cells. It is not
possible, on the basis of our data, to conclude that c-FLIP directly inhibits
AKT phosphorylation: c-FLIP might interact with other elements that
modulate this process. The ﬁndings shown in this work are in agree-
ment with our previous reports [26,27], in which we demonstrated
that AKT phosphorylation in muscle tissues of c-FLIP transgenic mice
is lower than in that of control animals.
It is noteworthy that in the present manuscript we found that phar-
macological inhibition of AKT completely rescued the PERK, though not
the IRE1, signalling pathway. This suggests that c-FLIP may also act on
elements other than AKT to modulate the activation of IRE1 cytosolic
targets. Further studies are warranted to shed light on this aspect.
5. Conclusion
In conclusion ourwork provides evidence indicating that c-FLIPmay,
besides performing its well-known anti-apoptotic function, also pro-
mote apoptosis following ER stress-inducing stimuli. Indeed, we dem-
onstrate that the absence of c-FLIP protects MEFs from cell death in
response to ER stress by modifying PERK and IRE1 signalling transduc-
tion pathways. We thus show, for the ﬁrst time, an important novel
role of c-FLIP as a modulator of the UPR.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cellsig.2016.06.003.
Acknowledgments
The authors thank Dr. Tak W. Mak for providing WT and c-FLIP-/-
MEFs, Marcus Peter for providing c-FLIPL plasmid and the researchers
from the “P. Valdoni” Department of Sapienza University for their
technical support. The authors also wish to thank Drs. Sara Palchetti,
Annarita Favia and Donatella Starace for their helpful suggestions. We
also thank Prof. A. Musarò for providing P-AKT T308 and mTOR
antibodies.
This work was supported by PRIN 2010–2011, Fondazione Roma
2013 and 2015 grants, “Ricerca Scientiﬁca Sapienza 2014” and “Ricerca
Scientiﬁca Sapienza 2015”to EZ.
The authors declare that they have no conﬂicts of interest.
References
[1] I. Tabas, D. Ron, Nat. Cell Biol. 13 (2011) 184–190.
[2] P. Walter, D. Ron, Science 334 (2011) 1081–1086.[3] K. Haze, H. Yoshida, H. Yanagi, T. Yura, K. Mori, Mol. Biol. Cell 10 (1999) 3787–3799.
[4] P. Tsaytler, H.P. Harding, D. Ron, A. Bertolotti, Science 332 (2011) 91–94.
[5] H.P. Harding, Y. Zhang, D. Ron, Nature 397 (1999) 271–274.
[6] S.J. Marciniak, C.Y. Yun, S. Oyadomari, I. Novoa, Y. Zhang, R. Jungreis, K. Nagata, H.P.
Harding, D. Ron, Genes Dev. 18 (2004) 3066–3077.
[7] A.L. Shaffer, M. Shapiro-Shelef, N.N. Iwakoshi, A.H. Lee, S.B. Qian, H. Zhao, X. Yu, L.
Yang, B.K. Tan, A. Rosenwald, E.M. Hurt, E. Petroulakis, N. Sonenberg, J.W. Yewdell,
K. Calame, L.H. Glimcher, L.M. Staudt, Immunity 21 (2004) 81–93.
[8] J.S. Cox, C.E. Shamu, P. Walter, Cell 73 (1993) 1197–1206.
[9] J.J. Credle, J.S. Finer-Moore, F.R. Papa, R.M. Stroud, P.Walter, Proc. Natl. Acad. Sci. U. S.
A. 102 (2005) 18773–18784.
[10] C. Hetz, P. Bernasconi, J. Fisher, A.H. Lee, M.C. Bassik, B. Antonsson, G.S. Brandt, N.N.
Iwakoshi, A. Schinzel, L.H. Glimcher, S.J. Korsmeyer, Science 312 (2006) 572–576.
[11] P. Hu, Z. Han, A.D. Couvillon, J.H. Exton, J. Biol. Chem. 279 (2004) 49420–49429.
[12] Y. Kimata, D. Oikawa, Y. Shimizu, Y. Ishiwata-Kimata, K. Kohno, J. Cell Biol. 167
(2004) 445–456.
[13] K.L. Lipson, S.G. Fonseca, S. Ishigaki, L.X. Nguyen, E. Foss, R. Bortell, A.A. Rossini, F.
Urano, Cell Metab. 4 (2006) 245–254.
[14] D. Luo, Y. He, H. Zhang, L. Yu, H. Chen, Z. Xu, S. Tang, F. Urano, W. Min, J. Biol. Chem.
283 (2008) 11905–11912.
[15] Z. Mounir, J.L. Krishnamoorthy, S. Wang, B. Papadopoulou, S. Campbell, W.J. Muller,
M. Hatzoglou, A.E. Koromilas, Sci. Signal. 4 (2011) ra62, http://dx.doi.org/10.1126/
scisignal.
[16] J.P. Munoz, S. Ivanova, J. Sanchez-Wandelmer, P. Martinez-Cristobal, E. Noguera, A.
Sancho, A. Az-Ramos, M.I. Hernandez-Alvarez, D. Sebastian, C. Mauvezin, M.
Palacin, A. Zorzano, EMBO J. 32 (2013) 2348–2361.
[17] M. Irmler, M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J.L. Bodmer, M.
Schroter, K. Burns, C. Mattmann, D. Rimoldi, L.E. French, J. Tschopp, Nature 388
(1997) 190–195.
[18] C. Scafﬁdi, I. Schmitz, P.H. Krammer, M.E. Peter, J. Biol. Chem. 274 (1999)
1541–1548.
[19] A. Golks, D. Brenner, C. Fritsch, P.H. Krammer, I.N. Lavrik, J. Biol. Chem. 280 (2005)
14507–14513.
[20] R. Katayama, T. Ishioka, S. Takada, R. Takada, N. Fujita, T. Tsuruo, M. Naito, J. Cell Sci.
123 (2010) 23–28.
[21] J. Zhang, Y. Chen, Q. Huang, W. Cheng, Y. Kang, L. Shu, W. Yin, Z.C. Hua, Int. J.
Biochem. Cell Biol. 41 (2009) 1678–1684.
[22] E.S. Marini, C. Giampietri, S. Petrungaro, S. Conti, A. Filippini, L. Scorrano, E. Ziparo,
Cell Death Differ. 22 (2015) 1131–1143.
[23] M.E. Peter, Biochem. J. 382 (2004) e1–e3, http://dx.doi.org/10.1042/BJ20041143.
[24] D.W. Chang, Z. Xing, V.L. Capacio, M.E. Peter, X. Yang, EMBO J. 22 (2003) 4132–4142.
[25] C. Giampietri, S. Petrungaro, P. Coluccia, A. D'Alessio, D. Starace, A. Riccioli, F. Padula,
S.M. Srinivasula, E. Alnemri, F. Palombi, A. Filippini, E. Ziparo, P. De Cesaris, Cell
Death Differ. 10 (2003) 175–184.
[26] C. Giampietri, S. Petrungaro, P. Coluccia, F. Antonangeli, K. Giannakakis, T.
Faraggiana, A. Filippini, G. Cossu, E. Ziparo, Cell Death Dis. 1 (2010) e38, http://dx.
doi.org/10.1038/cddis.
[27] C. Giampietri, S. Petrungaro, M. Musumeci, P. Coluccia, F. Antonangeli, P. De Cesaris,
A. Filippini, G. Marano, E. Ziparo, J. Hypertens. 26 (2008) 1008–1016.
[28] P.M. Chaudhary, M.T. Eby, A. Jasmin, A. Kumar, L. Liu, L. Hood, Oncogene 19 (2000)
4451–4460.
[29] A. Koenig, I.A. Buskiewicz, K.A. Fortner, J.Q. Russell, T. Asaoka, Y.W. He, R. Hakem, J.E.
Eriksson, R.C. Budd, J. Biol. Chem. 289 (2014) 1183–1191.
[30] C. Quintavalle, M. Incoronato, L. Puca, M. Acunzo, C. Zanca, G. Romano, M. Garofalo,
M. Iaboni, C.M. Croce, G. Condorelli, Cell Death Differ. 17 (2010) 1908–1916.
[31] C. Giampietri, S. Petrungaro, S. Conti, A. Facchiano, A. Filippini, E. Ziparo, Biochim.
Biophys. Acta 1851 (2015) 929–936.
[32] C. Giampietri, S. Petrungaro, F. Padula, A. D'Alessio, E.S. Marini, A. Facchiano, A.
Filippini, E. Ziparo, Apoptosis 17 (2012) 1210–1222.
[33] C. Hetz, E. Chevet, S.A. Oakes, Nat. Cell Biol. 17 (2015) 829–838.
[34] W.C. Yeh, A. Itie, A.J. Elia, M. Ng, H.B. Shu, A. Wakeham, C. Mirtsos, N. Suzuki, M.
Bonnard, D.V. Goeddel, T.W. Mak, Immunity 12 (2000) 633–642.
[35] M. Ogata, S. Hino, A. Saito, K. Morikawa, S. Kondo, S. Kanemoto, T. Murakami, M.
Taniguchi, I. Tanii, K. Yoshinaga, S. Shiosaka, J.A. Hammarback, F. Urano, K.
Imaizumi, Mol. Cell. Biol. 26 (2006) 9220–9231.
[36] T. Hosoi, K. Hyoda, Y. Okuma, Y. Nomura, K. Ozawa, Brain Res. 1152 (2007) 27–31.
[37] G.A. Ngoh, K.N. Papanicolaou, K. Walsh, J. Biol. Chem. 287 (2012) 20321–20332.
[38] T. Verfaillie, N. Rubio, A.D. Garg, G. Bultynck, R. Rizzuto, J.P. Decuypere, J. Piette, C.
Linehan, S. Gupta, A. Samali, P. Agostinis, Cell Death Differ. 19 (2012) 1880–1891.
[39] S.R. Datta, H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, M.E. Greenberg, Cell 91
(1997) 231–241.
[40] M.H. Cardone, N. Roy, H.R. Stennicke, G.S. Salvesen, T.F. Franke, E. Stanbridge, S.
Frisch, J.C. Reed, Science 282 (1998) 1318–1321.
[41] A. Brunet, A. Bonni, M.J. Zigmond, M.Z. Lin, P. Juo, L.S. Hu, M.J. Anderson, K.C. Arden,
J. Blenis, M.E. Greenberg, Cell 96 (1999) 857–868.
[42] M. Garofalo, C. Quintavalle, C. Zanca, R.A. De, G. Romano, M. Acunzo, L. Puca, M.
Incoronato, C.M. Croce, G. Condorelli, PLoS ONE 3 (2008) e4070, http://dx.doi.org/
10.1371/journal.pone.0004070.
